I. Chen

759 total citations · 1 hit paper
9 papers, 587 citations indexed

About

I. Chen is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Molecular Biology. According to data from OpenAlex, I. Chen has authored 9 papers receiving a total of 587 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 4 papers in Cancer Research and 3 papers in Molecular Biology. Recurrent topics in I. Chen's work include Renal cell carcinoma treatment (5 papers), Economic and Financial Impacts of Cancer (3 papers) and Renal and related cancers (3 papers). I. Chen is often cited by papers focused on Renal cell carcinoma treatment (5 papers), Economic and Financial Impacts of Cancer (3 papers) and Renal and related cancers (3 papers). I. Chen collaborates with scholars based in United States and United Kingdom. I. Chen's co-authors include Robert J. Motzer, Robert A. Figlin, Michael Baum, Santosh Hariharan, Dongrui R. Lu, Brian I. Rini, Martin Gore, Thomas E. Hutson, S. T. Kim and M. Dror Michaelson and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

I. Chen

9 papers receiving 579 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

2011 446 citations Brian I. Rini, Dongrui R. Lu et al. JNCI Journal of the National Cancer Institute profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
I. Chen United States	7	422	322	234	203	85	9	587
S. Srinivas United States	13	527 1.2×	410 1.3×	282 1.2×	264 1.3×	137 1.6×	38	816
Angel H. Bair United States	13	704 1.7×	559 1.7×	435 1.9×	330 1.6×	75 0.9×	17	1.0k
Thorsten Ruf Switzerland	9	498 1.2×	180 0.6×	388 1.7×	148 0.7×	209 2.5×	20	807
Lisa Cupit United States	9	647 1.5×	404 1.3×	462 2.0×	217 1.1×	27 0.3×	15	891
Sasja F. Mulder Netherlands	12	340 0.8×	265 0.8×	253 1.1×	130 0.6×	19 0.2×	38	669
L. Wood United States	12	333 0.8×	254 0.8×	185 0.8×	126 0.6×	13 0.2×	23	481
Nora Sánchez United States	13	140 0.3×	261 0.8×	139 0.6×	187 0.9×	50 0.6×	19	498
Robert C. Whorf United States	10	477 1.1×	346 1.1×	418 1.8×	200 1.0×	25 0.3×	20	790
Rachael Lawrance United States	9	729 1.7×	191 0.6×	394 1.7×	460 2.3×	49 0.6×	25	957
Mark R. Olsen United States	12	591 1.4×	257 0.8×	416 1.8×	174 0.9×	13 0.2×	20	774

Countries citing papers authored by I. Chen

Since Specialization

Citations

This map shows the geographic impact of I. Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Chen more than expected).

Fields of papers citing papers by I. Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I. Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Chen. The network helps show where I. Chen may publish in the future.

Co-authorship network of co-authors of I. Chen

This figure shows the co-authorship network connecting the top 25 collaborators of I. Chen. A scholar is included among the top collaborators of I. Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I. Chen. I. Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Chen, I., Astrid Botty van den Bruele, Erin F. Gillespie, et al.. (2020). Salvage of Locally Recurrent Breast Cancer with Repeat Breast Conservation Using 45Gy Hyperfractionated Partial Breast Re-Irradiation. International Journal of Radiation Oncology*Biology*Physics. 108(3). e41–e42. 1 indexed citations

Rini, Brian I., Dongrui R. Lu, I. Chen, et al.. (2011). Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. JNCI Journal of the National Cancer Institute. 103(9). 763–773. 446 indexed citations breakdown →

Zurita, Amado J., Daniel J. George, Neal D. Shore, et al.. (2011). Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. Annals of Oncology. 23(3). 688–694. 33 indexed citations

Motzer, Robert J., Robert A. Figlin, Thomas E. Hutson, et al.. (2007). Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors. Journal of Clinical Oncology. 25(18_suppl). 5024–5024. 71 indexed citations

Patel, Premal H., G. Varuni Kondagunta, Bruce G. Redman, et al.. (2007). Phase I/II study of sunitinib malate in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. 25(18_suppl). 5097–5097. 6 indexed citations

O’Dwyer, Peter J., Patricia LoRusso, A. DeMichele, et al.. (2007). A phase I dose escalation trial of a daily oral CDK 4/6 inhibitor PD-0332991. Journal of Clinical Oncology. 25(18_suppl). 3550–3550. 13 indexed citations

Cella, David, J.C. Cappelleri, Andrew G. Bushmakin, et al.. (2007). Quality of life (QOL) predicts for progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib compared to interferon-alpha (IFN-α). Journal of Clinical Oncology. 25(18_suppl). 6594–6594. 6 indexed citations

Ronnen, Ellen A., G. Varuni Kondagunta, Christopher Lau, et al.. (2006). A phase I study of sunitinib malate (SU11248) in combination with gefitinib in patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. 24(18_suppl). 4537–4537. 10 indexed citations

Kelly, William K., Matthew D. Galsky, Eric J. Small, et al.. (2004). Multi-institutional trial of the epothilone B analogue BMS-247550 with or without estramustine phosphate (EMP) in patients with progressive castrate-metastatic prostate cancer (PCMPC): Updated results. Journal of Clinical Oncology. 22(14_suppl). 4509–4509. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact